Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

REGENXBIO Inc. RGNX

Healthcare  —  Biotechnology
7.40 0.16 2.21% as of 25 Sep
Market cap
$487.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

REGENXBIO Inc. (RGNX) Business Profile

Updated before January 2025

Company Overview

REGENXBIO Inc. (NASDAQ: RGNX) is a leading clinical-stage biotechnology company specializing in the development, commercialization, and licensing of gene therapy products. Founded in 2009 and headquartered in Rockville, Maryland, REGENXBIO is at the forefront of advancing gene therapy solutions to treat a wide range of genetic diseases. The company was co-founded by Dr. Ken Mills, who also serves as the President and Chief Executive Officer. Under his leadership, REGENXBIO has grown into a prominent player in the biotechnology sector, leveraging its proprietary NAV® Technology Platform to develop innovative therapies.

The company’s mission is to improve lives through the curative potential of gene therapy. Its leadership team includes experienced professionals from the biotechnology and pharmaceutical industries, such as CFO Vittal Vasista and Chief Scientific Officer Olivier Danos, Ph.D. Their collective expertise has been instrumental in driving the company’s research and development efforts.

Core Business Segments

NAV® Technology Platform

REGENXBIO’s core business revolves around its proprietary NAV® Technology Platform, which is a suite of adeno-associated virus (AAV) vectors used for delivering therapeutic genes to target cells. This platform is the backbone of the company’s gene therapy programs and has been licensed to multiple partners for various applications.

Internal Pipeline

The company’s internal pipeline focuses on developing gene therapies for rare and chronic diseases. Key programs include:

  • RGX-314: A gene therapy candidate for the treatment of wet age-related macular degeneration (wet AMD) and other chronic retinal conditions.
  • RGX-121: Targeting mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
  • RGX-111: Designed for the treatment of mucopolysaccharidosis type I (MPS I).
  • RGX-181: Aimed at treating late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease.

Licensing and Partnerships

REGENXBIO also generates revenue through licensing its NAV® Technology Platform to other biotechnology and pharmaceutical companies. This segment includes partnerships with industry leaders such as Novartis, Pfizer, and Ultragenyx, enabling the development of gene therapies for a broader range of diseases.

Business Model

REGENXBIO operates on a dual business model that combines in-house development of gene therapies with licensing its proprietary technology to external partners. This approach allows the company to:

  1. Generate Revenue: Through milestone payments, royalties, and licensing fees from its NAV® Technology Platform.
  2. Advance Internal Programs: By focusing on high-impact therapeutic areas with significant unmet medical needs.
  3. Collaborate Strategically: Partnering with other companies to expand the application of its technology while sharing development risks.

The company’s revenue streams are diversified, with a mix of product sales, licensing income, and collaboration agreements.

Strategic Direction

REGENXBIO is committed to advancing its pipeline of gene therapy candidates and expanding the applications of its NAV® Technology Platform. Key strategic priorities include:

  • Pipeline Expansion: Advancing clinical trials for RGX-314, RGX-121, and other candidates while exploring new therapeutic areas.
  • Global Reach: Expanding its presence in international markets through strategic partnerships and collaborations.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its operations and supply chain.
  • Innovation: Investing in research and development to enhance the efficacy and safety of its gene therapy products.

The company also aims to achieve regulatory approvals for its lead candidates and bring them to market, addressing significant unmet medical needs.

Competitive Landscape

REGENXBIO operates in a highly competitive biotechnology sector, facing competition from companies specializing in gene therapy, such as:

  • Bluebird Bio: Focused on gene therapies for severe genetic diseases.
  • Sangamo Therapeutics: Specializing in genomic medicine and gene editing.
  • UniQure: A pioneer in AAV-based gene therapies.
  • Spark Therapeutics: Known for its FDA-approved gene therapy, Luxturna.

Despite the competition, REGENXBIO’s proprietary NAV® Technology Platform and robust pipeline provide a competitive edge.

Risk Factors

Like any biotechnology company, REGENXBIO faces several risks, including:

  • Regulatory Challenges: The approval process for gene therapies is complex and time-consuming.
  • Market Dependence: Reliance on a limited number of product candidates and licensing agreements.
  • Supply Chain Disruptions: Potential delays in manufacturing and distribution of gene therapy products.
  • Competition: Intense competition from other biotechnology companies.
  • Financial Risks: High research and development costs and dependence on external funding.

Recent Developments

In recent years, REGENXBIO has made significant progress in advancing its pipeline and expanding its partnerships. Notable developments include:

  • RGX-314 Clinical Trials: Positive interim data from ongoing trials for wet AMD and diabetic retinopathy.
  • Partnership with AbbVie: A collaboration to develop and commercialize RGX-314 globally.
  • Regulatory Milestones: Achieving orphan drug designation for RGX-121 and RGX-111.
  • Manufacturing Expansion: Investing in state-of-the-art manufacturing facilities to support commercial-scale production.

These developments underscore the company’s commitment to innovation and growth.

Investment Considerations

Strengths

  • Proprietary NAV® Technology Platform with broad applications.
  • Robust pipeline targeting high-value therapeutic areas.
  • Strategic partnerships with leading biotechnology and pharmaceutical companies.
  • Strong leadership team with extensive industry experience.

Risks

  • High dependence on a few key product candidates.
  • Regulatory and competitive challenges.
  • Financial risks associated with clinical trials and commercialization.

Investors should weigh these factors when considering REGENXBIO as a potential investment.

Conclusion

REGENXBIO Inc. is a pioneering biotechnology company with a strong focus on gene therapy. Its proprietary NAV® Technology Platform, robust pipeline, and strategic partnerships position it as a leader in the field. While the company faces challenges typical of the biotechnology sector, its innovative approach and commitment to addressing unmet medical needs provide a solid foundation for future growth. As the gene therapy market continues to expand, REGENXBIO is well-positioned to capitalize on emerging opportunities and deliver long-term value to patients and investors alike.